Get ready for some serious hype

Finally at long last the S-1 for Livongo has arrived and judging by the press coverage the company is receiving one just might think this is somehow a watershed event. Listen digital health as we’ve been saying is hotter than Georgia asphalt, so we aren’t surprised. Nor does it hurt any that Livongo’s primary target are patients with diabetes a chronic disease state that is growing at epidemic rates. Not like we need to add gas to a raging forest fire but it sure as hell doesn’t hurt either that patients with poor controlled diabetes . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.